Viridian Therapeutics (NASDAQ:VRDN - Get Free Report ) was downgraded by research analysts at LADENBURG THALM/SH SH from a "buy" rating to a "neutral" rating in a report released on Thursday, Marketbeat Ratings reports.
Get Viridian Therapeutics alerts:
Sign Up
A number of other research analysts also recently commented on VRDN. Needham & Company LLC reaffirmed a "buy" rating and issued a $30.00 target price on shares of Viridian Therapeutics in a research report on Thursday. B. Riley lowered Viridian Therapeutics from a "buy" rating to a "neutral" rating and dropped their price objective for the stock from $25.00 to $20.00 in a report on Thursday. Wedbush upped their target price on Viridian Therapeutics from $39.00 to $40.00 and gave the company an "outperform" rating in a research report on Wednesday, February 28th. Finally, HC Wainwright reiterated a "buy" rating and issued a $37.00 price objective on shares of Viridian Therapeutics in a research note on Thursday, February 29th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $34.60.
Check Out Our Latest Report on Viridian Therapeutics
Viridian Therapeutics Stock Down 6.6 % Shares of VRDN stock traded down $0.99 on Thursday, reaching $13.91. 1,729,471 shares of the stock were exchanged, compared to its average volume of 927,377. Viridian Therapeutics has a twelve month low of $10.93 and a twelve month high of $28.35. The company has a current ratio of 18.26, a quick ratio of 18.26 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $887.74 million, a price-to-earnings ratio of -2.61 and a beta of 1.14. The business's 50 day moving average price is $16.46 and its 200 day moving average price is $17.64.
Viridian Therapeutics (NASDAQ:VRDN - Get Free Report ) last issued its earnings results on Wednesday, May 8th. The company reported ($0.79) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.28. The business had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.09 million. Viridian Therapeutics had a negative return on equity of 121.80% and a negative net margin of 75,711.48%. The business's quarterly revenue was down 26.5% on a year-over-year basis. During the same quarter last year, the company earned ($1.61) EPS. As a group, sell-side analysts expect that Viridian Therapeutics will post -4.39 earnings per share for the current fiscal year.
Institutional Trading of Viridian Therapeutics Several hedge funds have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Viridian Therapeutics by 122.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,369 shares of the company's stock worth $182,000 after purchasing an additional 4,610 shares in the last quarter. Arizona State Retirement System acquired a new position in Viridian Therapeutics during the fourth quarter worth about $208,000. Principal Financial Group Inc. lifted its position in shares of Viridian Therapeutics by 9.7% during the 1st quarter. Principal Financial Group Inc. now owns 11,915 shares of the company's stock valued at $209,000 after acquiring an additional 1,058 shares during the period. Raymond James & Associates boosted its stake in shares of Viridian Therapeutics by 71.1% during the 3rd quarter. Raymond James & Associates now owns 15,164 shares of the company's stock worth $233,000 after acquiring an additional 6,303 shares in the last quarter. Finally, Dark Forest Capital Management LP acquired a new stake in shares of Viridian Therapeutics in the 3rd quarter worth approximately $264,000.
Viridian Therapeutics Company Profile (
Get Free Report )
Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
Read More
Before you consider Viridian Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list.
While Viridian Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
